Coya Therapeutics, Inc.
As of Oct 22, 2026, Coya Therapeutics is in Stage 2, the uptrend phase, now in week 3 (since Oct 8, 2026). It closed at $4.14, 43.8% below its 52-week high and below its 200-day average, which is falling.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is COYA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
COYA among Biotechnology306th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …306 | COYA | Stage 2 · wk 3 | 30 | −17.9% |
Coya Therapeutics: quick answers
What stage is Coya Therapeutics in?
As of Oct 22, 2026, Coya Therapeutics (COYA) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 8, 2026 and is in week 3. What the four stages mean
Is Coya Therapeutics in an uptrend?
Yes. Coya Therapeutics is in a Stage 2 uptrend. It trades 11.3% below its 200-day average, which is falling.
How far is Coya Therapeutics from its 52-week high?
Coya Therapeutics closed at $4.14 on Oct 22, 2026, 43.8% below its 52-week high of $7.36. Its 52-week low is $3.78.
How has Coya Therapeutics performed over the past year?
As of Oct 22, 2026, Coya Therapeutics is down 36.0% over the past year and down 26.7% so far in 2026.
Which sector and industry is Coya Therapeutics in?
Coya Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.